A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

NCT07584226 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

NRAS Mutation
NRAS-mutant Advanced Melanoma
NRAS-mutant Solid Tumors
NRAS Q61R
NRAS Q61K
NRAS Q61L
NRAS Q61H
NRAS G12D
NRAS G13R
NRAS G13D
NRAS G12V

Interventions

DRUG: RLY-8161

Sponsor

Relay Therapeutics, Inc.